-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 Qc2eMrMpfD58SGyibOREruioEXt36wfj+/1P6bqaCTvj4VAiqiBeEY5LQEttGdNB
 YrJXOx9IbM1TG6EQGjQTuw==

<SEC-DOCUMENT>0000950123-09-071232.txt : 20091216
<SEC-HEADER>0000950123-09-071232.hdr.sgml : 20091216
<ACCEPTANCE-DATETIME>20091216160503
ACCESSION NUMBER:		0000950123-09-071232
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20091215
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20091216
DATE AS OF CHANGE:		20091216

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CHAMPIONS BIOTECHNOLOGY, INC.
		CENTRAL INDEX KEY:			0000771856
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				521401755
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0430

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-17263
		FILM NUMBER:		091244660

	BUSINESS ADDRESS:	
		STREET 1:		2200 WILSON BLVD
		STREET 2:		SUITE 102-316
		CITY:			ARLINGTON
		STATE:			VA
		ZIP:			22201
		BUSINESS PHONE:		703-526-0400

	MAIL ADDRESS:	
		STREET 1:		2200 WILSON BLVD.
		STREET 2:		SUITE 102-316
		CITY:			ARLINGTON
		STATE:			VA
		ZIP:			22201

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CHAMPIONS SPORTS INC
		DATE OF NAME CHANGE:	19920703

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INTERNATIONAL GROUP INC
		DATE OF NAME CHANGE:	19860319
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>c93787e8vk.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="margin-left: 0.25in; width: 7.2in; font-family: 'Times New Roman',Times,serif">
<DIV style="font-size: 10pt">
<DIV style="font-size: 1pt; width: 100%; border-bottom: black 2pt solid">&nbsp;</DIV>
<DIV style="font-size: 1pt; width: 100%; border-bottom: black 1pt solid">&nbsp;</DIV>

<P style="font-size: 14pt" align="center"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION<BR>
<FONT
style="font-size: 12pt">Washington, D.C. 20549 </FONT></B>

<P style="font-size: 18pt" align="center"><B>FORM 8-K</B>

<P style="font-size: 12pt" align="center"><B>CURRENT REPORT<BR>
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934</B>

<P style="font-size: 10pt" align="center"><B>Date of Report (Date of earliest event reported): December 15,
2009</B>

<P align="center">&nbsp;

<P style="font-size: 24pt" align="center"><B>CHAMPIONS BIOTECHNOLOGY, INC.<BR>
</B><FONT
style="font-size: 10pt">(Exact name of registrant as specified in its charter) </FONT>
<TABLE style="font-size: 10pt; text-align: center" cellspacing="0" cellpadding="0" width="100%" border="0">

 <TR>
  <TD width="32%">&nbsp;</TD>
  <TD width="1%">&nbsp;</TD>
  <TD width="33%">&nbsp;</TD>
  <TD width="1%">&nbsp;</TD>
  <TD width="32%">&nbsp;</TD>
 </TR>
 <TR valign="bottom">
  <TD style="border-bottom: #000000 1px solid"><B>Delaware</B></TD>
  <TD>&nbsp;</TD>
  <TD style="border-bottom: #000000 1px solid"><B>0-17263</B></TD>
  <TD>&nbsp;</TD>
  <TD style="border-bottom: #000000 1px solid"><B>52-1401755</B></TD>
 </TR>
 <TR valign="top">
  <TD>(State or other Jurisdiction of Incorporation)</TD>
  <TD>&nbsp;</TD>
  <TD>(Commission File Number)</TD>
  <TD>&nbsp;</TD>
  <TD>(IRS Employer Identification No.)</TD>
 </TR>

</TABLE>
<TABLE style="font-size: 10pt; text-align: center" cellspacing="0" cellpadding="0" width="100%" border="0">

 <TR>
  <TD width="49%">&nbsp;</TD>
  <TD width="1%">&nbsp;</TD>
  <TD width="49%">&nbsp;</TD>
 </TR>
 <TR valign="bottom">
  <TD style="border-bottom: #000000 1px solid"><B>Science and Technology Park at Johns Hopkins<BR>
855 N. Wolfe
Street, Suite 619, Baltimore, MD<BR>
</B></TD>
  <TD>&nbsp;</TD>
  <TD style="border-bottom: #000000 1px solid"><B>21205</B></TD>
 </TR>
 <TR valign="top">
  <TD>(Address of Principal Executive Offices)</TD>
  <TD>&nbsp;</TD>
  <TD>(Zip Code)</TD>
 </TR>

</TABLE>


<P style="font-size: 10pt" align="center">Registrant&#8217;s telephone number, including area code: <B>(410)
369-0365</B>
<TABLE style="font-size: 10pt; text-align: center" cellspacing="0" cellpadding="0" width="30%" border="0">

 <TR>
  <TD width="100%">&nbsp;</TD>
 </TR>
 <TR>
  <TD style="border-bottom: #000000 1px solid" nowrap><B>Inapplicable<BR>
</B></TD>
 </TR>
 <TR>
  <TD nowrap>(Former name or former address if changed since last report.)</TD>
 </TR>

</TABLE>


<P style="font-size: 10pt" align="left">Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

<P style="font-size: 10pt" align="left"><FONT face="Wingdings">o</FONT> Written communications pursuant to Rule
425 under the Securities Act (17 CFR 230.425)<BR>
<BR>
<FONT face="Wingdings">o</FONT> Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)<BR>
<BR>
<FONT face="Wingdings">o</FONT>
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))<BR>
<BR>
<FONT face="Wingdings">o</FONT> Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))<BR>


<P>&nbsp;
<DIV style="margin-top: 10pt; font-size: 1pt; width: 100%; border-bottom: black 1pt solid">&nbsp;</DIV>
<DIV style="font-size: 1pt; width: 100%; border-bottom: black 2pt solid">&nbsp;</DIV>
</DIV>

<P style="font-size: 10pt" align="center">

<P style="display: none; font-size: 10pt" align="center">1
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="margin-left: 0.25in; width: 7.2in; font-family: 'Times New Roman',Times,serif">

<P style="font-size: 10pt" align="center"><B>INFORMATION TO BE INCLUDED IN THE REPORT</B>

<P>
<TABLE style="font-size: 10pt" cellspacing="0" cellpadding="0" width="100%" border="0">
<TR style="font-size: 10pt; background: none transparent scroll repeat 0% 0%; color: #000000" valign="top">
  <TD nowrap align="left" width="3%"><B>Item&nbsp;2.02.</B></TD>
  <TD width="1%">&nbsp;</TD>
  <TD><DIV style="text-align: justify"><B>Results of Operations and Financial Condition.</B></DIV></TD>
</TR>
</TABLE>

<P style="font-size: 10pt; text-indent: 4%" align="justify">On December&nbsp;15, 2009, Champions Biotechnology,
Inc. (the &#8220;<B>Company</B>&#8221;) announced its results of operations for its fiscal quarter ended
October&nbsp;31, 2009. A copy of the Company&#8217;s press release announcing such results dated December 15, 2009
is attached hereto as Exhibit&nbsp;99.1. This Form 8-K and the attached exhibit are furnished to, but not filed
with, the Securities and Exchange Commission (&#8220;<B>SEC</B>&#8221;) and shall not be deemed to be incorporated
by reference into any of the Company&#8217;s filings with the SEC under the Securities Act of 1933.

<P>
<TABLE style="font-size: 10pt" cellspacing="0" cellpadding="0" width="100%" border="0">
<TR style="font-size: 10pt; background: none transparent scroll repeat 0% 0%; color: #000000" valign="top">
  <TD nowrap align="left" width="3%"><B>Item&nbsp;9.01.</B></TD>
  <TD width="1%">&nbsp;</TD>
  <TD><DIV style="text-align: justify"><B>Financial Statements and Exhibits.</B></DIV></TD>
</TR>
</TABLE>

<P style="font-size: 10pt" align="justify"><I>(c)&nbsp;Exhibits</I>

<P style="font-size: 10pt" align="justify">The following exhibits are filed herewith:

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" cellpadding="0" width="100%" border="0">
<!-- Begin Table Head -->
<TR valign="bottom">
  <TD width="8%">&nbsp;</TD>
  <TD width="3%">&nbsp;</TD>
  <TD>&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
  <TD valign="top"><DIV style="margin-left: 0px; text-indent: 0px">Exhibit&nbsp;No.</DIV></TD>
  <TD>&nbsp;</TD>
  <TD valign="top" align="left">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
  <TD style="border-top: #000000 1px solid" valign="top"><DIV style="margin-left: 0px; text-indent: 0px">&nbsp;</DIV></TD>
  <TD>&nbsp;</TD>
  <TD valign="top" align="left">&nbsp;</TD>
 </TR>
<TR valign="bottom">
  <TD valign="top"><DIV style="margin-left: 0px; text-indent: 0px">99.1 </DIV></TD>
  <TD>&nbsp;</TD>
  <TD valign="top" align="left">Press Release dated December&nbsp;15, 2009</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<P style="font-size: 10pt" align="center"><B>SIGNATURES</B>

<P style="font-size: 10pt; text-indent: 4%" align="justify">Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.

<P style="font-size: 10pt; margin-left: 51%" align="justify"><B>CHAMPIONS BIOTECHNOLOGY, INC.</B><BR>
(Registrant)


<P style="font-size: 10pt" align="justify">Date: December&nbsp;16, 2009

<P style="margin-top: -11pt; font-size: 10pt; margin-left: 51%" align="justify">By: <U>/s/ Douglas D.
Burkett&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>
<BR>
Douglas D. Burkett <BR>
President

<P style="font-size: 10pt" align="center">

<P style="display: none; font-size: 10pt" align="center">2
</DIV>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>c93787exv99w1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
<TITLE>Exhibit 99.1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->

<DIV style="margin-left: 0.25in; width: 7.2in; font-family: 'Arial',Arial,sans-serif">

<P style="font-size: 10pt" align="right"><U><B>Exhibit&nbsp;99.1</B></U>

<P style="font-size: 10pt" align="center"><IMG height="67" alt="Press Release Header"  src="c93787p9378701.jpg" width="632">

<P style="font-size: 10pt" align="center"><B>Champions Biotechnology Reports Fiscal 2010 Second Quarter Financial
Results</B>

<P style="font-size: 10pt" align="justify"><B>Baltimore, MD, December&nbsp;15, 2009</B>&#8212;<U>Champions
Biotechnology, Inc</U>. (OTC Bulletin Board: CSBR), a company engaged in the development of advanced preclinical
platforms and tumor specific data to enhance the value of oncology drugs, today announced its financial results
for the second fiscal quarter ended October&nbsp;31, 2009. Full details of Company&#8217;s financial results are
available in the Company&#8217;s Form 10-Q at <U>www.championsbiotechnology.com</U>.

<P style="font-size: 10pt" align="justify">Total revenues for the second quarter of 2010 were $1,289,000 as
compared to $1,044,000 in fiscal 2009, an increase of 23%. The overall increase was derived from the
Company&#8217;s Preclinical eValuation business which generated revenues of $700,000 for the second fiscal quarter
of 2010 compared to $180,000 for the corresponding quarter a year ago, an increase of 289%. Revenues from
Personalized Oncology Services for the second fiscal quarter of 2010 were $589,000 as compared to $864,000 in
fiscal 2009, a decrease of 32%. The overall reduction resulted from a decrease in panel revenues during the
quarter partially offset by increases in Personalized Tumorgraft implantations and associated drug studies as well
as vaccine studies as the Company focused on growing this more strategic area of the Personalized Oncology
business.

<P style="font-size: 10pt" align="justify">Costs of Preclinical eValuation services for the second fiscal quarter
of 2010 totaled $350,000 as compared to $90,000 in fiscal 2009. The cost of Preclinical eValuation expenses
increased proportionally with the additional revenues which were generated in the quarter.

<P style="font-size: 10pt" align="justify">Costs of Personalized Oncology Services for the second quarter totalled
($13,000) as compared to $369,000 in fiscal 2009. This reduction is due to the decrease in Personalized Oncology
panel services year over year. In addition, during the quarter the Company recognized a one-time $125,000 credit
and change in estimate for accrued costs of a personalized oncology study agreement. <BR>
Research and development
(&#8220;R&amp;D&#8221;) expenses for the second quarter of fiscal 2010 were $645,000 as compared to $417,000 in
the comparable quarter of fiscal 2009, an increase of 55%. This increase is primarily due to licensing fees and
costs of $208,000 in connection with licensing our second oncology drug, TAR-1.

<P style="font-size: 10pt" align="justify">General and administrative expenses for the second fiscal quarter of
2010 were $891,000 as compared to $354,000 in the comparable quarter of 2008. This increase is primarily due to
our development of corporate infrastructure to support our effort to grow our Preclinical eValuation Services and
includes increased payroll, legal, accounting, marketing, and office rent expenses.

<P style="font-size: 10pt" align="justify">For the second quarter ended October&nbsp;31, 2009 the Company reported
a net loss of $584,000 or ($0.02) per share compared to a net loss of $161,000 or $0.00 per share for the
corresponding quarter in fiscal 2009.

<P style="font-size: 10pt" align="justify">The Company&#8217;s cash position on October&nbsp;31, 2009 was $394,000
compared to $1,728,000 at April&nbsp;30, 2009.

<P style="font-size: 10pt" align="justify">For the six-month period ended October&nbsp;31, 2009, revenues were
$2,251,000 compared to $1,717,000 for the comparable period last year, an increase of 31%. Total operating
expenses which include research and development and general and administrative, were $2,838,000 compared to
$1,337,000 for the comparable period last year, an increase of 112% and the Company reported a net loss of
$1,587,000 or $0.05 per share, as compared to a net loss of $292,000 or $0.01 per share for the comparable period
in fiscal 2009.

<P style="font-size: 10pt" align="center">

<P style="display: none; font-size: 10pt" align="center">3
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="margin-left: 0.25in; width: 7.2in; font-family: 'Arial',Arial,sans-serif">

<P style="font-size: 10pt" align="justify">Doug Burkett, Ph.D. President of Champions Biotechnology, Inc.
commented. &#8220;This past quarter we saw continued revenue growth and exceptional progress in our primary
objective to in-license a pipeline of high potential oncology drugs. The Company continued to make progress during
the quarter on the following fronts.&#8221;

<P>
<TABLE style="font-size: 10pt" cellspacing="0" cellpadding="0" width="100%" border="0">

 <TR style="font-size: 10pt; background: none transparent scroll repeat 0% 0%; color: #000000" valign="top">
  <TD style="background: none transparent scroll repeat 0% 0%" width="2%">&nbsp;</TD>
  <TD nowrap align="left" width="3%">1.</TD>
  <TD width="1%">&nbsp;</TD>
  <TD>
<DIV style="text-align: justify">The Company&#8217;s quarterly top line revenues increased 23% year over
year.</DIV>
</TD>
 </TR>

</TABLE>


<P>
<TABLE style="font-size: 10pt" cellspacing="0" cellpadding="0" width="100%" border="0">

 <TR style="font-size: 10pt; background: none transparent scroll repeat 0% 0%; color: #000000" valign="top">
  <TD style="background: none transparent scroll repeat 0% 0%" width="2%">&nbsp;</TD>
  <TD nowrap align="left" width="3%">2.</TD>
  <TD width="1%">&nbsp;</TD>
  <TD>
<DIV style="text-align: justify">Champions entered into an exclusive licensing agreement with Ramot of Tel Aviv
University for TAR-1, a therapeutic for the treatment of cancer.</DIV>
</TD>
 </TR>

</TABLE>


<P>
<TABLE style="font-size: 10pt" cellspacing="0" cellpadding="0" width="100%" border="0">

 <TR style="font-size: 10pt; background: none transparent scroll repeat 0% 0%; color: #000000" valign="top">
  <TD style="background: none transparent scroll repeat 0% 0%" width="2%">&nbsp;</TD>
  <TD nowrap align="left" width="3%">3.</TD>
  <TD width="1%">&nbsp;</TD>
  <TD>
<DIV style="text-align: justify">Champions entered into an exclusive licensing agreement with Yale University and
Southern Research Institute for the repurposing of Bithionol for Oncology.</DIV>
</TD>
 </TR>

</TABLE>


<P>
<TABLE style="font-size: 10pt" cellspacing="0" cellpadding="0" width="100%" border="0">

 <TR style="font-size: 10pt; background: none transparent scroll repeat 0% 0%; color: #000000" valign="top">
  <TD style="background: none transparent scroll repeat 0% 0%" width="2%">&nbsp;</TD>
  <TD nowrap align="left" width="3%">4.</TD>
  <TD width="1%">&nbsp;</TD>
  <TD>
<DIV style="text-align: justify">The Company began Tumorgraft testing of its oncology drug, SG410.</DIV>
</TD>
 </TR>

</TABLE>


<P>
<TABLE style="font-size: 10pt" cellspacing="0" cellpadding="0" width="100%" border="0">

 <TR style="font-size: 10pt; background: none transparent scroll repeat 0% 0%; color: #000000" valign="top">
  <TD style="background: none transparent scroll repeat 0% 0%" width="2%">&nbsp;</TD>
  <TD nowrap align="left" width="3%">5.</TD>
  <TD width="1%">&nbsp;</TD>
  <TD>
<DIV style="text-align: justify">Champions entered into a collaboration agreement with Ortho Biotech Oncology
Research &amp; Development for the evaluation of a preclinical oncology therapeutic.</DIV>
</TD>
 </TR>

</TABLE>


<P>
<TABLE style="font-size: 10pt" cellspacing="0" cellpadding="0" width="100%" border="0">

 <TR style="font-size: 10pt; background: none transparent scroll repeat 0% 0%; color: #000000" valign="top">
  <TD style="background: none transparent scroll repeat 0% 0%" width="2%">&nbsp;</TD>
  <TD nowrap align="left" width="3%">6.</TD>
  <TD width="1%">&nbsp;</TD>
  <TD>
<DIV style="text-align: justify">The United States Patent and Trademark Office issued a patent in September for
the Company&#8217;s tubulin inhibitors, including its oncology compound SG410.</DIV>
</TD>
 </TR>

</TABLE>


<P style="font-size: 10pt" align="justify"><B>About Champions Biotechnology, Inc.</B> <BR>
Champions
Biotechnology, Inc. is engaged in the development of advanced preclinical platforms and predictive tumor specific
data to enhance and accelerate the value of oncology drugs. The Company was co-founded by David Sidransky, M.D.
who with Manny Hidalgo, M.D., Ph.D. developed the Company&#8217;s Preclinical Platform; a novel approach based
upon the implantation of primary human tumors in immune deficient mice followed by propagation of the resulting
engraftments (Biomerk Tumorgrafts&#8482;) in a manner that preserves the biological characteristics of the
original human tumor. Early studies suggest that these Tumorgrafts closely reflect human cancer biology and their
response to drugs is predictive of clinical outcomes in cancer patients. Champions Biotechnology leverages its
preclinical platform to evaluate drug candidates and to develop a portfolio of novel therapeutic candidates
through pre-clinical trials. As drugs progress through this early stage of development, the Company plans to sell,
partner or license them to pharmaceutical and/or biotechnology companies, as appropriate. The Company also offers
its predictive preclinical platform and tumor specific data to physicians for personalized patient care and to
Companies for evaluation of oncology drugs in models that integrate prognostic testing with biomarker discovery.
Champions Biotechnology is dedicated to enhancing preclinical development tools, accelerating development and
valuation of oncology drugs, and advancing personalized treatment with a goal to improve the lives of cancer
patients globally. For more information regarding Champions Biotechnology&#8217;s growing business and recent
news, please visit <U>www.championsbiotechnology.com</U> or <U>www.personalizedcancertreatment.com.</U>

<P style="font-size: 10pt" align="justify"><I>This press release contains &#8220;forward-looking statements&#8221;
(within the meaning of the Private Securities Litigation Act of 1995) that inherently involve risk and
uncertainties. Champions Biotechnology generally uses words such as &#8220;believe,&#8221; &#8220;may,&#8221;
&#8220;could,&#8221; &#8220;will,&#8221; &#8220;intend,&#8221; &#8220;expect,&#8221; &#8220;anticipate,&#8221;
&#8220;plan,&#8221; and similar expressions to identify forward-looking statements. One should not place undue
reliance on these forward-looking statements. The Company&#8217;s actual results could differ materially from
those anticipated in the forward-looking statements for many unforeseen factors. See Champions
Biotechnology&#8217;s </I><I>Form 10-K</I><I> for the fiscal year ended April&nbsp;30, 2009 for a discussion of
such risks, uncertainties and other factors. Although the Company believes the expectations reflected in the
forward-looking statements are reasonable, they relate only to events as of the date on which the statements are
made, and Champions Biotechnology&#8217;s future results, levels of activity, performance or achievements may not
meet these expectations. The Company does not intend to update any of the forward-looking statements after the
date of this press release to conform these statements to actual results or to changes in Champions
Biotechnology&#8217;s expectations, except as required by law.</I>

<P style="font-size: 10pt" align="justify">CONTACT:

<DIV style="font-size: 10pt; margin-left: 4%" align="justify">The Investor Relations Group, Inc.<BR>
James Carbonara<BR>
+1-212-825-3210
</DIV>

<P style="font-size: 10pt" align="center">

<P style="display: none; font-size: 10pt" align="center">4
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>c93787p9378701.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 c93787p9378701.jpg
M_]C_X``02D9)1@`!``$`8`!@``#__@`?3$5!1"!496-H;F]L;V=I97,@26YC
M+B!6,2XP,0#_VP"$``("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("
M`@("`@,#`@(#`@("`P0#`P,#!`0$`@,$!`0$!`,$!`,!`@("`@("`@("`@,"
M`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`__$`:(```$%`0$!`0$!```````````!`@,$!08'"`D*"P$``P$!
M`0$!`0$!`0````````$"`P0%!@<("0H+$``"`0,#`@0#!04$!````7T!`@,`
M!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I
M*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'
MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7
MV-G:X>+CY.7FY^CIZO'R\_3U]O?X^?H1``(!`@0$`P0'!00$``$"=P`!`@,1
M!`4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)B<H
M*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H*#A(6&
MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76
MU]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_``!$(`$,">`,!$0`"$0$#$0'_V@`,
M`P$``A$#$0`_`/W\H`*`"@##\2^(M)\(>']9\3Z[<BRT;0-.N]5U&X(W&*UL
MX6FEV(.9)6"[40<N[*HY85U8+!XC'XO#8'"0]IB,54A2IQVO*;25WT2O>3V2
M3;T1R8[&X?+<'BL=BY^QPV#ISJU);VA!.3LNLGM&*UDVDM6?DYXR_P""AGQ$
MO=3G'@7POX:T#1$E<6AUV"\UC6)X0<))=F"^MK6V=U^8Q11R;"<>:^,G]\RW
MP@R>C0C_`&ICL3B<2TN94)0HT8OJH*5.<Y)=)2<;[\JV/YWS3QGSF=>2RC`8
M;!X6+?+[>,ZU9KHY.-2%.+>[C&+MMSRW?L?[/_[<L_C7Q/I?@?XGZ+I6D7^N
MW4.G:)XDT+[1;Z;)J5PWEVMCJNGWEQ.UJUS,R11W,,Y02.BO$BL9%^=XL\+H
M97@:^9Y'B:M>CA(RJ5L-7Y745.*O*=*I",%+D5Y2A*-^5-QDVN5_3<'>+$LT
MQV'RK/<-2PM;%3C3H8FAS0INK)VA"K3G*;CSR:C&<9VYFDX)7FOT<K\;/VT*
M`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`
MH`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`
M"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@!NY1QD#VR
M!3L^P72\CP+]J/1M0\0?`'XFZ=I.][Q=`&HB&')DFMM'O[/5KZ%57EB]E97`
MVCKT[U]9P-B*6"XLR2M7M&E[?V=WHHRK4YTH/RM.<=?F?'\?8:MB^#\]H8:_
MM%056T=W"C4A6J))=X0EIU/Y]J_K<_C0[OX7Z-?>(/B1X"T330WVW4?&'AV"
M!E.#$?[5M9))R1]U8HDDE+=A&3VKR<]Q-'!9+FV*KM1HT,)B)2OHG>E)*/K)
MM12ZMI'L</86MB\]RC"T$_:U<7AXQM]F]6-Y>2BKR;[)L_I-K^,3^XPH`*`"
M@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`
M*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@
M`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`X[4/$D2S/!;.!'$
MQ1I`?OL#AMI!X0'(SW^E>G1P,N52DM7JEV3[^9QU,3'F<8NRCI?^N@W3[JZU
M)V2U'RQX\R5B1''NZ`D=6/H.>].M3AATG-V;V2W?^2\PIRE-VALMWT1T!TR.
M2*2&Z<SQ31O%-"541212H4EB=#G<C(S*0>H)KB]NX24J:Y'%IQ?5-.Z:VLT]
M4;NC%Q<)^]&2:<>C35FFNS6C/YZ?'/PY71/&OB_1])=+C2]*\3:Y8:;/"Q>*
M2QM=2N8;5HW4D.OD*@W`D'&:_K[*LW6)RS+L173IUZ^&H5*D7HU.=.,I76EO
M>;T/XJS?(,5A,US+#87EEAL/BJ].E))M.G"I*,&FM_=2UZGHO[/7P[DU?XF:
M?IDU[9Z7>7>EZQ#HMUJ#2Q6_]K/:8AMQ)'\T=Q-;&[2,J"=Y4*"Q`/Y9X]8#
M,N)_"WB/(,DQ,<+B<Q^JPJU)<ZBL-#$TZM9-TKSBI>SC!R2?+&3;5KGWO@]A
MX95Q[E&.S6GS4<-#$RHJR7^T2H3A3^*RO:<G%73<DDM6C]"X-9^-/PA>*#5O
M-U;0T94C&I.^K::4&0L=OJT9^T6+$=(Y6`_Z9FO\Y\/C_%#PVE3H8^53,LIB
MU&*Q4I8S"\O2-/%Q?MZ#M\,*DDO^G;/[8>'R/.$Y4$J%?=\G[J?JZ;]V7FTO
MF?0/@?XO>'/%YBLI@VA:VP`&G7TB^5<.1R+"\`5+@G'$;".3GA#UK]DX5\1L
MEXC=/"U4\IS26BPU>2Y*DNOU>MI"IY0:A4[0>Y\[C\DQ6`3J1_?T(_;@M8K^
M_'>/JKQ\SUBOT(\8*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`
M"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H
M`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`,
M+Q+?G2]`U6^4[6M[.0H1QM>3$2,/0AI`?PKJP-)5L7AZ724U=>2U?WV,,34]
MCAZLUIRQ=OGI^I\T_P#"0_[7ZU]M]41\U]8\_P`3VK1]?L-`^'S>);@-)!;6
MUW>31Q$"6XN!<R016R$\"2240Q+G@%@3P*^9Q.$JXK-U@J=HRE*$(M[1CRJ3
MD_))N3/9I8BGALN>*DO=A&4FENW=I17G)V2/C'QK\2?B7XS:Y@EU>?0M(FWH
M-(T)FLD,#\>5=7R8NKLE>&S(B'G"`'%?H^69+DN6*$HX>.)Q$+/VU?WWS+K&
M#]R'EHVOYFSX+,,PSC,.>+Q$L+0E=>RH^XN5])37OR\]4GV/%?\`A"0/^6.,
M?[/3/X5]+_:;_F/G?[&BOL;>0Y?!9C97CC:-XV5T=-R.CJ0RNCK@HZL`0P((
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M]J=1ZM^Y.[:9AFN60BI8K"1Y5'6I36B\Y02V_O1V6ZZH]^K]</FSY?\`VA_V
MH/"WP&@L],^POXF\:ZI;-=6'AVWN5M(;2R+/%'J6LWGER&TMI)D=(HHXI)9C
M%)M"JI<?<<(<#X[BF52LJJP&68>7+/$2CS.4[)NG1A>*E))IRDY*,+J[;?*?
M!<9\>Y?PC&G0]D\;FE>//3PT9<BA#5*I6G:3A&4DU"*BY3:?PQ3D?*LW[:O[
M07A^WMO$OBKX%P67@ZY>-TO9-)\7Z+$UO(PVF+6[[SK97=2-KR6X5B1@<U]W
M'PTX2Q4YX+`<4.IF---."K82JU);WHT^6=EU2G==6?`2\4.,,%"&-Q_"BI9;
M-IJ;H8N@G%O2U>;G3N[Z/D:?1'U-XZ_:)N]$_9ZM?CCX>\)W,,M]_8K6WA[Q
M8DUA(D6IZG'I\DKM9L6EMV5FFMYTVK/$T4F`LF!\+E?!]/$\7SX7Q>/BXT?;
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M9?-._:.,<5]+F?!F#P'!F`XFIXRM+$8M8=NC*,%3C[:_-9KWM+:7WZGR^5<;
MXS'<:X_A:>"HT\/@Y8E*M%S]HU1^%M.7+>76T5Y;:_3WC'Q3IG@?PIXA\7:Q
M((M,\.:1?:M=\A6=+2!Y5MXL_P#+::0)#&.[RJ.]?$9;@*^98_!Y=AE>MBZL
M*4.R<Y).3_NQ5Y2[)-GW>9YA0RG+\;F.)?+0P-&=:71M0BVHK^]-VC%=9-(^
M,OV9_P!L#5/C/XYOO!/BO0-!\/74^DSZCX<DTB:_8WL]C('O]/N1>SR`S"Q<
MW"&,)\MI/D=,?I'&OAW0X:RNEF6`Q5?%TX58T\0JJ@N2-16A4CR1C9<ZY)7O
MK.-NI^9<#>)-;B?-:N58_"4,'4E2E4PSI>T7/*#O.F^><KOV;<XM*.D)W6JM
M]=_$KQ3=>!_A_P",O&%C:V][=^&/#FK:W;6=T\D=M<S:?9RW,<$[P_.D3M&`
M2G.#Q7Y[DN`AF>;9;EU2<J-/&XBE1E**3E%5)J+E%/2ZO=7T/T;/,PJ93DV9
MYE2IQJ5,!AJU>,)-J,G3@Y*,G'5)VUMJ?+7[,W[77_"Z_$6J^#_%.BZ5X7\0
MK9C4O#T>FW5U-;:Q;6X/]IVO^F?,E_;H8YU120\/G-@>0V[[KC7P^_U8P>'S
M'`XFKC<)S^SQ#J1C&5&4OX4O<TY)N\6W\,^5:\ZM\#P+XCKBC&XC+<=AJ6`Q
MD8>TPZIRERUHQO[6'OMM3BK323]Z'.[+DN[W[3G[5Z_`W5-#\+^&M'TOQ+XH
MO8'U/6+74;JX@M='TI\QV'F&S.\WUW,LKK&Q7;#!O8$31FLN".`7Q/0Q6.QF
M(J8'`TI*G1E3C%RK55K.W/IR4TTFUO.5E\,C7COQ#CPEB,+@,%AZ>,Q]6+JU
MHSE)1HTGI33Y&GSU'>25_=A%-KWXLZ/Q#^T!KVC?LR:9\=(?#^D2ZW?:;H-\
M^A27%XNE1OJ^M6^F2HDZ'S]L<4Q=<\E@`>*XL'PEA<1QM7X6>+JQPU*I7@JR
MC#VMJ5&55-Q^#WFK/R.[&\88K"<"T.*XX2E+$U:=";H-S5)>VKQI.S3YM%+F
M6N^E['R_9_MP_'.[TI?$-M\"8+WPZ$EF?6+&T\72Z8T%O(\=S(NI16DMNJ1O
M'(KN2RH48-]TU]S4\,.%Z5?ZG/BET<9=)49SPD:G-))Q7LG*,[R332T<DU;<
M^#I>*O%-7#K&4^%%4P5G+VT*6+]ERQ;4G[57II)IIN[46G?8^O/@;^T;X>^-
MWA'7=9TK3I=$\1^%[<OKGAN[N%N1`TEM//9W=G>11Q_:]-N&MYD$GE1.C1.C
MH/D:3\]XGX-QG"^887#5JJQ&#QLK4,1"/)>THJ<)P;?)4@I1;7-*,E)-/=+]
M&X4XVP7%.6XO$X>B\+C<!"]?#3ES<MXRE"<)I1<J<W&2NXQDG%IQ^&4N8_99
M_:(\0?'R'QI)KGAW1_#_`/PB\^BQ6PTFYO9_M(U1-2:4S_;/N%#8IMV=?,;/
M05W<=<'X3A*661PN,K8KZZJSE[6,(\GLW3MR\G?G=[[61P<`<:8OBZ.9O$X.
MC@_J#H*/LG-\WM?:\W-S-[>S5FK7N[K0Y;XY_ME:;\._$\OP]^'GAI_'WC>V
MN%L[]%DN!I6G:@X!&EQQ:?%)=:QJBYQ)!;^4L3?(TAD5TC[N%_#BMF^!CF^;
M8U93EDH\]-VBJLZ?_/UNHXTZ-)_9E/F<EJHJ+4GP<5^)E#)<>\FR;!/-LTIR
MY*B3E[*G4?\`RZ4::<ZU5/248N"B_=YG-2C'R.V_;@^+/@G5=/C^,OP5GT'1
M;]_DN+/3]?\`#^HK"W+2V4/B`RV^IO&OS&`36[,/XUS7T$_##(,RP]5\-\21
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MO$UYATU2VP9C$"1)`SNH'D29^OXT\/:G#.&HYA@*]3&X"_)7<XQC.A-OW)-0
MT=*=^7FTY9V3^.)\;P-XCTN*,56RW'8>GE^8)<^'C"4N2M!*]2*YVVJL$N?E
MO[T.9I+DE?8_:)_:0\1?!?QO\/O"NC>'-%UBU\8HK7=UJ5S?03V9;6+;32+=
M+4A&'ESL_P`_\0`Z5S\'\&8/B3+,WQV(QE;"SRYVA&G&#C+]U*I[W-JM5;3H
M=/&?&V+X7S7)\OPV"HXB&9).4JCFI0;JJG[O*TMG?5/7IWZC]H_]HW3/@'I&
MD)#H[>(_%OB1[E-#T7SVM;6."T\I;G4-1GCCDD6W6:X@BCAB0R3.Y"E1&S#A
MX-X-K\58C$-XA8'+\$HNM6Y>:7-.[C3IQ;4>9J,I2E)\L$DVFVD=_&W&N'X/
MP^&4<,\9F.-<E0H\W)%1A92J5))-V3E&,8Q5YMNSBHMKYBC_`&T/CCX3O=+G
M^)GP#NM.T'5KB"&TDLM.\2Z+?3FZ95@BL9=72YMKR\8NNRW;R'D)"@KGC[9^
M&W"^.I5X9)Q7&KBL-&3DIU,-6A'EUDYJDX3A#O-<RBM;,^%CXG<59=5P\L\X
M2G0PF(E%0<*.*P\WS;*#K>TC.>ND+1<NZ/TIL+EKVQL[Q[6YL'N[6WN7L;U$
MCO+)IX4E:UNTBD=$N8BQCD5'=0R,`Q')_&*L%1JU*4:D:JI2E%3@VX32;7-!
MM)N,K7BVD[-72/V^C4=6E2JNG*@ZD(R=.:2G3<DGR32;2E&]I)-JZ=F]RW69
MH%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!
M0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`'(^/;:6Z\&^)
M(8`3*-)NIXU7JS6J?:@JC^\?)P!ZFO0RJ<:698)RTBJL8ORYWR_J<>81<L%B
M8QW5.32_PKF_&Q\$#Q#P/WA]>OK7ZO\`4UV/SWZVN_\`3/3?#GB^/6O"EWX&
MF?\`?MJ<.HV63Q-:*'EN[;_?CN4BF"]Q(Y_@KQ,9ESPN/IYG!6@J<J<^G+/1
M1EZ.+<6^EEW/5PF-CB,)/`-^]SJ<.EXJ[E'Y-*2]7V#_`(10?\\A^1_PH^NO
M^8T^IK^4/^$4'_/(?D?\*/KK_F#ZFOY0_P"$4'_/(?D?\*/KK_F#ZFOY0_X1
M0?\`/(?D?\*/KK_F#ZFOY3ZB\!)N\'Z;97"AUMX9]/='Y5H(Y9(TC8'JOV=D
M7'H*^#SJG3GC<5&45*G75Y1:T:G%*::[2=[][GU.7.4,+02;C*EHO*ST^Y6/
M!M5T!=.U2_M(MRI:WDT<+`X98UD)A(/4,$V<^HK^;LPRA8+'XO#TU:.'K3C!
MJ]U%2?(TUU2MKW/T"CB'.C2FVO?BFUYM:_C<^BO"6J2:KH=I/.<W4`-K=,>K
MS0`#S3[R1E'/NYK]FX=Q\\?E6'JU7_M%*]*J]FYPLN9^<XN,GYMGRV-HK#XB
M<8:0E[T5V3Z?)W1^6NDV=AXN_P""@6KVOC=([J'3_$6K-I%EJ`5K>6;0/#GF
M^&8!%+\KHB00W<<>,-)$IP=W/].5ZE7+O"7#SRMNG*KAZ7M9T]))5\1;$RNM
M4VY2IR>ZBWM8_FC#TJ.8^,6(IYI:<:.)J^QIU-8N6'P[>&C9Z62A"I%;.26]
M]?UFO+.SU"UN+&_M;:]LKJ)X+JSO((KFUN8)5*R0W%O,K1S1.I(9'4@@X(K\
M!IU*E"I"K1J2HU*;4HSA)PE&2U3C*+3BT]FFFC^B:E*G6ISHU:<:M*:<90G%
M2A*+T<91DFFFMTU9GR5^V]''#^SGXCAAC2**+5?"D<44:K'''''K=FJ1QHH`
M1%4`!0````*_0/#%N7&."E)N4I4L4VV[MMT9MMMZMM[L_./%:,8\$XV,4HQC
M6PB22LDE7@DDEHDEHDMCXW^#GQ5_:W\.?#;PQHWPX^%D&O\`@NR@OET/5W\,
M:A>M>PRZI?3W3F[@UN!)ME_+=19$2X\K;SMR?T7B/(?#_%YUCL1G&>RP>95)
M0]M16)ITU!JE",5R2HR<;P496YGO?J?FO#&?^(N"R+`8;),BABLLI1J>PJO"
M5IN2=:I*;YXUH1E:HYQTBK6MT%_9;U/Q1K'[8&NZKXUTU=&\6W^G^,KGQ!I2
MVSV:V&IR16AN+<6LLTKP!3CY6D<C^\:..:&!POAYA,/EE;ZQE]&I@XX>HY*?
M/33ERRYDHIW[J*]`X`KYAB/$G&5\TH+"YC4AC)5Z2@Z:IU&ES14).3C9]&V_
M,]P_X*"?$S^RO"OASX5Z==+#>^+KI-:U[#E!#H.E7"K80W&W[L-UK`$O0\:0
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MOBC]G'Q[XDT>9;C2]>^%VL:MI\RD?/::AH4ES"6VDA7"2`,O4,"#R*_">'L)
M6R_C+*<%B(^SKX3,Z-*<=K3A749?*ZNGU6I^_<28NAC^",XQV&ES8?%Y56K4
MW_<J4'->CL]5T=T?D#X/^'OB;1OA)I/[1O@2ZNH];\`_$*\L];AB#.+33[6W
MT6YTS6$C7&^T2YOKBSOHCE7@O$8X1937]#9CF^!Q&?U^#<TIQ^JYME\)T&].
M:I*5:-6BWTFXPC4HR6JG!I>\XG\W99DN.PO#N'XUR><HXO)\QG"M%)ODIQC0
MG2K)*UX*=25.M'9QG%NT5-ESQ;X&\5>+_A7XO_:9\?3W']J^+_&^EZ?X<APT
M$-S:SRWB:GJ$<+$F/2X!:0:=8Q`X"6DQY"QLV>7YI@,NSW+N"LHA&.'R[!5:
MF(>[C**@Z=-M6O5ESRK5Y;N4X]7)+7,<HS#,>'\RXYSB<EB,QQM.GAHVY5*,
MG4]K44=6J4.2-"A&^BA+=1@W]A^.?^4>7A[_`+%_P9_ZEEC7YUE?_)WL7_U_
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M%8G`5HSKR4E)T](4X0G):>UG[TYQWC:+=N9'J>%F3YA1H\0Y[B<,\'A<PH2I
MX>#BX*=W.I.<(NW[J'NQA+:3<DG[K*?_``3SEN+?0OC7/9IYEW`OAV6UCQG?
M<1V7B-X$QWW2JHQ[UIXO1A+%<,PJ/EIR^L*3[1<\.I/Y*YCX,2G#"<42I+FJ
M16&<%WDH8IQ7S=C%_P""?&GZ3K7CWXG>*-<\J[\965E836$UX%EO(DUS4-4?
MQ%J$/F`LEP]S#8PR3+A@MTR$XF8-T^+E6OA,IR/`X2]'+:DZBJ*'NPO1ITEA
MZ;MIRJ+J2C%Z7BG:\5;E\&J.'Q6;Y]C\7:IF=*G3E3<]9KV]2J\345]5)R5.
M,I+6TVKVF[_>G[1^A>'==^"/Q(M_$T5L;*Q\*ZMJ]I<3JFZQUC3+.:[TB[M9
M'&8KH7Z0QJ4(+B9HN5E(/Y5P;BL9@^)\EE@7)5*F*I4I1C=*=&K-0JQDEO'V
M;DW?1-*6\4S]>XWPF"Q7"N>0QT8^RHX2M6A*27[NM2@YT91;VE[11BK:R4G#
M52:?P]^RM?ZG/^R;^T#8W+2MIFG67C7^S-^=D4EWX($^H00D\*@E\F4J.`UR
MS=7.?T_CJE0I\?\`"-2FE&O5G@_:6T;4<;:G)^;7-&_:*70_*/#^M7EX=\94
MIMNA0IXWV5]DYX&]2,?*_+*W>3?4^4_`GPG\4WWPBO?CIX`O=0A\3?#;QM)]
MOMK(_P"DV^CV6FZ3J4&NZ:$&YI["YN)FN82&5[9V<C$#K)]YFN?8&CQ!2X6S
M:E3^HYS@E[.4_A=:=2K3E0J7T4:L8KV<M&JB2WDFOS[)^'<?4X=K<69/5J0Q
MV1XY^TC#24:,*=&K&O3LKWHSDW4B[ITWS;0DI=K\8OC78_''7O@'X@")9^(]
M*6#2?%NFQJRPVNKIXETUUNK0GAK"^AQ<1`$F/<\3$M%N;S.'.&:O"^%XKP=W
M/!5^:KA*C>LJ3P]1<LNTZ;]R7\VDUI*R]7B7BFCQ3C.$,7;V6.PZ5'%TTFE&
MLL1!\\/[E5/GBKMQ;<&VXW?W9^U]^SSXO^+8\*>+OA]<VQ\5>#DNH!I-U=)8
M-?VDMS!?6\VG7LV(8-1MKN!F"3M&DBS?ZQ6C`D_+/#SB_+N'?K^79M"2P&8N
M,O:QBY^SDHRA)5(+WG3G"5FXIN+7PM2;7ZUXD<&9CQ&LOS')YQ6898IQ]E*2
MINI&4E.+ISE:,:D)IZ2<5)2OS)Q2E\^P?M7_`+0GPFNM.T?X^?#`:MI/GVZ_
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MC?KD.P*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`
MH`*`"@`H`*`"@`H`*`"@`H`^?_VL?^36/VEO^R`?&3_U77B.@#\F/^"3WQA\
M7_#G3?`WP6^)4D$/@'XZZ/XO\>_L]:R\Q$2:YX2\7:_X8^(7@:::78L=_/=Z
M))K,%I&'V"?>9'DU>.&``]H_X+5_\FL>`?\`LO\`X6_]5U\5:`/H#_@J/_R8
MG\<_^Z9?^KB^'U`'QA\$/^"1/[-OQ*^"_P`(?B-KOC;XX6FM^/OA?X`\:ZQ:
MZ3XD\!P:5;:KXJ\*:3KNH6^F07GPUNKB'3X[N_F2%)[FXD6-4#RR,"[`'V_^
MR_\`\$]/@O\`LF>/M7^(WPY\3_%#6M;UKP?J'@JZM?&NM>%-1TJ/2M1UKP_K
ML]Q;P:%X*T>X34%N_#=BB.]R\8CEG!B9F1X@#Q__`()_>?\`#?XY?MS_`+/%
MY!:6L7A7XU#XG^&Q:W#NLOA_XD17<MI";=X(O(>T\/Z;X/\`,*EU\W49(P2L
M"23@;>5C+_X*16-[\;?B%^RE^QUI6H7&EP_%OX@ZCXS\;7]G?-;W5AX.\#Z=
M*;GR[(6<\=_-)IEYXIO[5;H"W6]\-6?F*0YFM`#O/^"7?BC55^`?B/X*>*)Q
M+XQ_9O\`BCXY^%.N`7;WD;0VNN7FJ6<EI-.$G;3(KJ]U73K;SHH=L.C+&B*D
M:H@!R_QD\_XJ?\%/OV9?`,$%I+HWP&^%WC'XO:]++</YR7WB;[;HUE;P6BP,
MHN+?5M-\"7(9Y4W1WTK<-;QK<`'*?'>_^)/[4W[;]_\`L?6?Q/\`'/P2^%'P
MR^&=O\1O$]WX*FET#Q)\3-0OXO#?^CZ9K:7)6\TBV7QEI\"1S036T=QH.M-+
M;7$\-M+:`'/^-O\`@FUJ?[.'P]\5?$;]C_XY_M"Z)\1_!FGW_B_3O"%QJVC>
M)-+\<3:/9/<W/A]?"WAKPII2:QK%]:6P@M;>YM-62YF2"U:TD\Y3$`?J!\"/
M'/B;XD?!_P"'WC;QIX2USP'XQUOP[;2>*_"7B+0]7\-ZKHOB2S>73=<@DT;7
M;*UOK2SDU*SN9[0S0*);2XMIHVDBF260#;RL>L,JNK(ZAD92K*PRK*PPRD'J
M""1BFFTTT[-:KY`TFFFM'I8_+'XLZ'=_#GQMJFA2JT>GS2-J6A3,"$N-)NY'
M:$(V`&>W??;R8Z-!GHPS^ZY!BJ>;Y90Q47^]@O9UHK>-6*7-==%-6G'REY,_
M&L\IU,HS"MAI7C2D_:47LG2DW:WG%WA+S7FCSNW\4SV4\-U:W+6]Q;2++!-&
MVUXI%.5=3ZY_`]#P:]>>!A.$J<X<T))IQ:T:>Z/)AF4J<HSA/EE!WBT[--'U
MQ\-?C%X6\4BWT?Q%<VFA>(OEBCEG9+?2]5?H&@N'(2TNF[P2,JDG]VQSM'P&
M<\.XW+W+$8.$L3@]VHINK27]Z*UE'M*.J7Q+J?=9/Q'@<:H4,5.&&Q>R<FHT
MZK_NR>D)/^65DW\+Z'T-_8"``[,+@,#@;=IY#`]-I'.1Q7R/UJU];*._2WKV
M/J_J^WNVOM_7F-70HB#L"D#J4VL![':>*F.,B[\DXR2_EDG;[F/ZLU]CE]=!
MW]@)_<_057UKS%[#^Z=MH$":=ICHV$CCFFE)/`"D*Q/Z&O(Q]:*G*K)\L803
M;[)7;._"P<8*"5GS.R]3S.^LS>7MU=E-IN)Y9<8Z!V)4?]\X%?D6*HO$XK$8
MAQY76J2G;LF]%]UCZBG/V5.%-?826]MM_O.W\%V[6UO?1XVKY\3J.@!,9#8_
M!5KZOA:DZ%'%PVC[2#735Q:?Y(\['R3E3?6S_/\`X<^1/VG/V7?$OC?Q/8?%
MOX1:A'I/Q#TT6+WMD;L:6^J7&E;?[,U73-3.([/6H(DCA(G*131PQ9=&C/G?
MOO!''&"RK`U>'^(*+K916YU"?)[14HU;^TI5*6\J,FW).*<H2E+W9)KE_%..
M^`<;FF/H\1<.5EALYH<CG3Y_9.K*E;V56E4NE"M%*,6IN,91C%\T7%\_CM[J
M/_!0;QGIQ\$W&A2>'XKF/[#?^(X8?#N@74EN1LFDEURWU!_(#)G=)IL,<K`G
M9][!^BI4?"3+*W]IPQ2Q+IOGIX=O$5XJ6Z2H2IJ]GLJTG%==KGS=6MXPYG0_
MLJ>$E@XU%[.IB(K#4)\MK2<JT9V5UNZ"4GTO<^@?B]\*?BOK'[+,7PYN=0/Q
M(^(L$OAT7-Y;?9M/:\CLM8M[AD^T:A<0B[-K9((VNYVCEN?),KH))"*^2X>S
M[(,+QT\XIT?[%R>2Q'+"7-/D=2C*-^6G&7)[2;YE3@G"GS<J?*DSZ_B7A[B'
M%<`1R25;^V\YA+#<TH\M-R4*T9-<U24.?V<%RNI-QG5Y>>4>9M'KG[-/A/Q#
MX&^"7@7PKXJTU]'U[2;758]0TZ2:VN'MGN->U2[A!FM)I86W6]Q"_P`DC??P
M>00/G^-,?@\SXFS3'8"LJ^$KRI.G42E%24:%*$M)J,E:46M4MCZ3@;+L9E'"
MN4Y?F%!X7%X:-95*;<9.//B*LXZPE*.L91>C>_<^;_AM\'?B3H?[8?CCXDZI
MX7N+/P1JMQXP?3]=:]TQX;A=26V%B5M8;UKI/-*/C?`N,?-BOLLYXBR7$>'>
M5Y+A\=&>9X>.$4Z"A53BZ?-S^\X*G[M^DG?I<^(R/AK.\'XDYKG=?`2I97B)
M8QTZ[G2<9*I\%HQJ.HN;S@K=;&#!^SWXT^,_[27BOQQ\:/!MUI_PVMH+VV\/
MZ?=:O:J=3LK`+I?AZR4:+J;7-HK1-<:K-\T7[UBA)\P@]<N+LMX9X,P&5\-9
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MU]I_B"RT/Q'I?@B";4='G_M6PUVPN9[?3HY[;4)(X)+;5);I,SO$HCN8`#A#
MCNS_`#/AR7'.39]EN8PJ82=?#U<:XTZL?93H3BI5'&5.+:G247[J;<HR;U:.
M#AW*N)J7`.><.YEEM2CC*>'Q-+`QE4HR]M"O3G*--.-248N%5R7ON*49P2T3
MMVW[(GPJ\2^"?@UK_@KXE^&1IL^L>)]>DNM%OIK"^BO=%U/2-(L7$QL;F>(P
MS"&ZC*%PV%.0`03YGB#GN"S'B/"9EDF-]K'#8:@HUH1G3<*U.M5FK<\823CS
M1DFE;S/4\..'\=E7#.,RK/,#["6)Q5=RH5'3FIT*M"C3?-[.4X\LN6<6KWLM
MM2W^U7\+-=\5_`RQ\`_#'PRMY-I6N>&AINA:?+96,5IH^DPW4&V%KVXAB6*&
M)H5V^9N.<\G-9\!Y[A<OXHJYKG>-=.->CB?:5ZBG-SK591E=J$92O)W=[6]#
M7Q!X?Q>/X3I9/D.!4WAZV'5*A3<*:A1I0G&T>>4(VBG%6YKOSU.0\6?"GX@7
M_P"Q?HWPPLO#D\WCJUT;PO;3^'Q>:<DT<]CXBM+V[C-V]VMJ3':QO(2)R#C`
M)/%>AE^?930\2<3G=3&1AE<ZN)E&OR5+-3P\H0?(H>T7-)I?#ZZ'FYEP]G%;
MPPPV0T<%*6;0I86+P_/34DZ>)A4FN9S5/2";^.SV3;/2OV:?A0OA#X/>#M'\
M<^"M%L?%^FG6&U!;W3M%OM0A:?7M2N;-I-0MUG$C?8YK<J1,Q52JY&W`\7C3
M/GC^(LQQ&59G6GEU7V/L^2I6ITW:A3C-*G+DLN=2O>*N[O6]SW.!N'5EG#66
MX;-<JH4<RH.NZG/3H3J+FQ%64&ZD>>[Y)1M:3LK+2UCZ*U6!Y])U*VMTW23:
M=>001KM7<\EM)'&@R0%RQ4<X`KX_#R4,11G-VC&I"4GY*2;9]IB(.6&KTX*\
MI4YQBEIJXM)=O(^'/V(/A'\1/A5;_$9/'WAJ?PXVM7/AQ]+$U[IMW]J6RCU@
M717^SKR?R_+-S!]_;GS.,X./T_Q.X@R?/)Y,\IQL<6L-'$*IRPJ0Y.=T>7^)
M"%[\LMK[:GY3X4\.9UP[#.HYO@98%XF6&=)2G2ES\BK\]O93G:W/'>U[Z=3@
M?BA^R_\`%GX<?$F[^+?[-=ZH:_N;N_N_#4=Q96MYI\U]*)]2L;>VU,K8ZUH%
MS-F46DK+)$<*B/Y4;IZV1\<9!G&2T^'N,Z6E&,80Q#C.4)J"M3G*5+][1KP6
MGM(IQFKMM<THOR,^X"XAR3/*G$?`]6SJRE4GAHRA"=-U'S5*<8U;4JV'F[M4
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MHPN_9SG&S<9*S=^ZLSY;^+G[&OC+0_B[I>O_``H\.G5_`NI:YIVN265O?:=:
M/X4FCU2WGU'3O*O[N%I=.`W36IB$A6,M`1F%6D^YX?\`$?+<3P]7PF?8SZMF
ME"C4HJ<H5)+$ITY*G4O3A)*H_AJ<UKRM-?$U'X'B/PQS+!\28?&<.X+V^4UJ
MU.NX1G3@\*U43J4[5)P;IKXJ3CS-1?(U>%Y?6G[2G@;]H?7M0\+>)O@GXQCT
M]/"PGFE\)QW$6DW.HZA/YB27TMU>%K'6;<VA$`T^_$,:;I'0N\I\OX#@O-.$
M,%1QV!XERYU'C>6*Q3BZD:=-6:@H0M5HRY[S]K2YI2T3Y5'7]&XXRGC+%UL!
MCN%LR5!9?S2>$C)495*DN9.;E-^QK1<;05*MRQC[TESN32^4O&7AG]MCX^:?
MIWP^\;^#](T'08-4M=0O=6N+?1])M?M-HLL,5[=W%OJ=W-<)$ES,XAT^`>82
M/E(`Q][EN-\,^$ZU;-LKS"KB<5*E*G"E&5:K+EDU)PA&5.G&+DXQ7-6EIWW/
MSW,\!XH<74:&39IEM+!X.-6-2=64:-&/-!2BI3E&I.4K*<G:A#5_9>A^F7PZ
M\&VOP\\"^%/!%G</=0>&-$L=)%VZB-KN6WA`N;LQ@D1>=<F64("=HD"Y.,G\
M4SC,9YMFF/S.I!4I8VM.KR+504G[L;Z7Y8V5]+VOU/W/)<LADV4Y?E5*;J1P
M%"G2YVK.<HKWIV^SS2O*W2]NAV=>:>H%`!0`4`%`!0`4`%`!0`4`%`!0`4`%
M`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`?/\`^UC_`,FL
M?M+?]D`^,G_JNO$=`'YH?L__`+/UQ\??^"7'P0L_"]R='^+'PZU?X@?$GX-^
M(XIOLTVC_$'PS\8OB'=Z7$\OER*;._57M'66.6-));:Z,;264>`#QO\`;[_:
M`L_VC?\`@GI\)/'$EG)H7C'3?VAO#_A+XE^$[I%MM1\*?$'P]\//BG9^(=,O
M=/+&;3XYI@E_;07"QS+::C;B9$F61$`/T4_X*C_\F)_'/_NF7_JXOA]0!\8?
M!#]@7]I+QC\%_A#XNT+_`(*(_'#P3HGBKX7^`/$FC>#-)@\>'2O".E:YX4TG
M4]/\,:8;/XWV%N=/TNTNH;&$P6-G'Y=HFRWA7$:`'Z'_`+*7[.'Q3_9]_P"$
M]_X67^TY\0/VC?\`A+?^$6_L3_A.H_$4?_"&_P!@_P#"1?VE_9?]O_$#Q-G^
MUO[:L//\C[#_`,@.W\SS\I]G`V/G+Q.O_"I?^"K'P^UU;86NB_M,_`O6?"%W
M<6K+&EUXP\#+)JOVO5H%V>?+'HGA7PMI\$[>=(/[02,;(D8J`'P(/_"Z_P#@
MHU^T[\7FD%WX<^`7A+PY\`_!MQ!;D69U:[FN;SQ:OVU_EN=2T_7M,\60R+!M
M$4.O0+(/FCDG`)?".[X'_P#!4'XA^&&VV?A7]K'X1Z3XYTEIK62"&?X@^`!<
MV=WIFFWJX@GN%TC3?%VJW=NP:8'7+20LB.BW('X$7[&:'XF?MC?MU?'N6WWV
M.G>,='^!?A._N626ZCM/!"_8/$MO8\,;32;N3PWX5U!8T=!*;A'EC$L9P`>O
M?&K]GGX#_M:>+[O7_`_QDN?!GQW^$3/X5UCQU\#/'^DKXZ\)))=:Q;Q^$?']
MCHU])<6<*:K9ZT8[6Z;3;V.?3[V&.X1$NH6`_`\>U'P9_P`%-/@%:3:[X7^+
MOPZ_:P\+Z5;I=7_@_P`:^$$\%>.;BSL2K7,'ANZT1@;W5+JS\T;]1UV[*2PQ
M&*UN'DD24#8^R/V6OVA_#_[4/P9\-?%OP_I=QX?;4Y+[2M?\-W5W#?3^'O$F
MD3?9]4TP7T"1K?6A)ANK6Y,-M)-:7UK++;V\KO!$`?0]`'COQI^$>G?%GPLV
MFF9--\0Z;YMUX<UDH6%I=LF'M;L)\TNFW05$F1>5*I*@+Q`-]'PUQ!6X?QRK
M*+JX.M:.(HWMS0OI*'15(7;@WH]8O23:^<XEX?IY_@'0C-8?&T+RPU:WP3:^
M":6KI5+)32U6DEK&S_&KQC:>)_A_X@O?"_B[3KG1=9L'(>"?/E7$))$=[87(
M_=WMA*!NCGB+*0<'#`J/Z0RV6!S;"4L=EU:.(PU5:2CHX/K"I'>$X[2C*S7F
MK,_F/-<3F.1XVKEV9T9X3%4'K&6THO:=.7PU*<MXSBVGY--&S\.=(O/B!K9T
MZ.[^PZ59HMSK.IE=XM+5F*I'$A.)+R=@RQH>/E9CD)@_#^)G&^5>&F11S+&4
MU7S#&SE1P&$<N15JL8\TZE22]Z.'H1<95917-)RA3A[U1-?3\!9+F''6;RP&
M%JO#X+"1C5QN)2YO94V[0A!;2K5FG&G%Z)*<Y>[!I_I1X-FTO1='M/"F@-J=
M[':C:D=YJ-S>O&[@;GN;BYD=82<`_9X$"IG`"U_%.8\=8_BO'5JN*J_6,76>
MM'#QCA\/172+C37*FK[/VE5_;G<_K/+^'L'D.#I87"1E3P]%:3K3E5JS?5\T
MW?7LN2"^S%(=KUGXJ\-31ZUIUX]E<0L)1$-SVTR#EH+F%VQ-"XX((!YR""`:
M^6S*EQ#D-6&:9?BY8.O3]]07,Z4UNZ=6#=JD);-.SZQ::37L47@<7!X:K352
M#TOHI1?>+7PM=+?,];^'OC_3O'6D3W26;66J:9<"RUC3E=9$MKDKOBFMY&PS
MVDZ9:,L`05=&R4R?TO@OQ!PW%F78BJL++"YEEM7ZOC<,I*4:=1QYH5*<G9RH
MUHWE3;BFFI0E>4&W\_F.3RRZM&'.I4:BYJ<[6;CU37247H[:.Z:T9V5RTT\?
MD*OE09W%%ZN>,;SQQP.!7N8VO7Q:Y.7V5+^5/5V_F>FGDM/4YJ5.%'5;KY6]
M$9W]GCT_05YOU/R-_:'2Z5:BTMB,;6E<R'M@8"J/R&?^!5]!EN'^K4+6Y74?
M-\K67X:_,Y*T^:>FBCH?.\WC_P"(=WJ7CE]/\2_#G1M.\)^(-5TRWT_Q'%<P
M7UY;Z>BSH_FQWR_+(CB/S`@RZM@<5^&5.-N-L3CN,98+/N&<JP7#698W"4L/
MF:JTJ]:GAHJI&7-&LKJ<6J?.HJ]12LE8^CCEV6PI8!5,+C*M3%T:<W.BXN$7
M-V>CCT>MK['4:3\3=8U6_P#A(SV5KI5CXWT?Q+J.MVTT<C2VS:-8?:()+.=W
M4QVKNK3`NC%HI$YSR?H<N\0<TS#'>&3EA*.78/B[!9MB<?2J1DYTW@,/[2G.
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M1:;YD^92MVT0_6/%_P`5/#?@2/Q1JFI^#I[C6;KPG%HOV73+^&"PAUR7_2WU
M03W0#A8I[?#1L`OER$Y!%5F?$_B+D?!M/B+,<?DE2MFE3*%@?98;$0IX>&.;
M=9XKVE2*:C&=*SA*T>6HW=-"H8+*<1F#P=&EB81H1Q#J<TX-R=)>[R6CI=I[
MK6Z.ET37?'%C=3ZCXG\9_#C5?#^E:=J.I:K:>&H+HZL+:TM)9?.AWWDBJB2B
M,MN7D':#EA7O93G/%F#Q%;'9_P`5<,9ADN6X;$XK&4<KC5EC%1H49SYZ:=5Q
MBHSY'*ZLU[J]Z29S5\-@90C2PF!QE#$U9PA3E6<53YI22L[16ZO;[S)TW7?C
M;XGTN+QAH-MX.TW2;Q/MNB^%-4COI-3U#3"2UNUYJT<J16=U<PX9`%5!O4MM
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M+Z!\0=)\-Z&D<#SPWNFWL<;-&TD%UB>YED;8LL9`&[[I(KXW.?$[B#!Y9Q?C
M\JC@L=+)>(\)EF`C"FZD*^&KQ4G%RIU?WE2;:C&I!JU](MGH8?)L)*ME]*LZ
ME%8C!U*U6[47"<6];..D5NT_O.MU#XJ&^\.>!]?\,B&,Z]XVT3PQK=C?PL]U
MI3W3SQZIITL:O&8+^&6,!788*E7"D.*^BQWB/+%Y#PAG7#\84WG6?Y?E./P^
M)@W5P<JSJ1Q>&G%2@Z>(I2BN2<E:4'&HH.,T<=/*/98G'X;%7_V;"U:]*4':
M,U&SA-.SO"2>J76ZO=$3>*/B+XUUG7[;X?-X<T3P_P"&=3GT676O$%M=W\VM
M:Q:!?ML-G;6LB+;V4+L$,K;F;<&7J55/B+C?BO-<ZH<%2RS*LDX?Q53`3QV8
M4ZU>IC<=1Y?;PH4Z?NTZ%*3Y93:<I7C*,FVX0:PF6X"AAY9BJU;$8J"JJE1E
M&"I4Y7Y7)O5REO;1='W>+>_%GQ-9^%->6]TW3M+\;^$O$_A[0=;ME$MUI5Q;
M:U?01P:EIX:5)!#<VCRL@=B4903D,`/(Q?B7G^%X<SJ.*P.&R_B[AG-,MR_'
MTDI5L)4I8ZM"-/%8=.<9JGB*3G*FI2;BTI/22BNBGD^%EB\/[.I.I@,70K5:
M4M(U$Z<6W">EKQE:]E9W/8_&GBJT\$^&=5\27D3SQZ;"IAM(B%EN[NXE2WL[
M2-B#L,MS+$A;!V@EL'&#^I<6<1X7A'A_,<^Q5.56&!A'DHQ=I5JU6<:5"C%V
M=O:59PBY6?+%N5G:S\3`X2>-Q5'"TVH.H]9/:,4G*4FO**;MU>AY+?Z_\;?#
MFD-XUUBS\(7VD6T*ZAJ_A#3XK^#5].TO`DG-OJDLC1W%[;P$O(K*4.QMN[%?
MFV,SKQ9R+*WQ7FF%R;%9;AX?6<;D^'C7IXO#8/XINGB9.4)XBA3?-63<X+EG
MR*=K'L4\-D6(K+`T)XBG6D^2GB).#ISJ;*\$DXQD]%:SU5[&KJWQ`\0>(M8T
M_P`-?#1=)BEG\.V7BK5_$>OI-)8:/I>IHLFG0I9V[JT]_,AW%6;:BG)Z,4]'
M,N-LZSS-,#D/`4<'"=;+*&;XW,\Q4WA\'A,5&,\-3C1IM.>(JQDIM2;C"+U5
ME.4,:.6X;"T*F)S/VEHUI4*=&C93J5(.TVY/2,$]-%=OY)TY]?\`BWIWA_6;
MTR^"=?O_``Y<6>H(NA//*_B30@KOJUN+'SR^E:A"@4Q2!I%E*NJQD[2W+6SK
MQ*P.39KB_:9#G.+R*K0Q,5@)3G+,\O2D\92]@I\^$Q%**BZ=1<RJM3A&E)\D
MIW'#9//$4*:6*PU/$J4/WMDJ-73V;YK6G"3^):-:-O>UX?$Z;Q=K'A+1/AS+
M:7']IVD/B'Q/J=U`US#X?T`G8;*6&.5`FMSW.Z%8G;]V8]Q5D;<O6O$&KQ-F
MG#64<#5*-?Z_1AF6;8JM3=6&6Y??E>'G",X*./JU;THTY2?LY14G&4)\\8_L
MJ."H8ROF2E3]E)T:%.+Y75J[\R=G^Z4?>;2UO:]U9]-\0O%.J>%W\%+I@M<:
M_P".-%\/7_VF)I,:??K=&<P;9$\NXS$FUSN`Y^4YKWN.>(\QX<EPC'+E2MG7
M$&`RS$>U@Y?[-B55=3V=I1Y*GN+ED^9+6\6<N6X2EB5CO:<R^K86K6ARNWOP
MY;7T=UJ[K3U.-\(_%N>]\?\`B;P5XCMX+../Q#JNE^$]4BB>"VOGTQU\_1[B
M1W9&U-8'AF0KM\P2%=H;9O\`E^%_$RMC>,^(.%,]HT\)3IYGC,)D^+A"5.E7
MEA))5,%5E*4HO%*G*G5@XN/M.=P<5)TE/MQF31I9=A<=A9.3]C3J8BFVG*"J
M;5(I)-0;3B][6O>U[4(/BUKZ^'[HQ:=8ZIXKU/XBZWX(\*Z>HDLK)UL94\N[
MU)_,9A#;VY9YF5E+$J!M!)''0\2\Z628ET\#0S#B/'\38_(<IPT5*C0Y</.*
MC6Q3YV^2C!N5:490YVXKW(\THZ2R?#?68)U)4,'2P=+%5YZ2E[Z=XP5DKR>D
M4T[:[['8:"/C%I^MZ?%XD;P?KNA7OFC4+G1TO-)O-#=8FDC:.*Z:0:E`\@6,
M`*KY.YB@&3]3DZ\4,%FV!I9Z\FS?)\6IK$U<&JV$K8"2@Y1<(U;_`%FG*5J:
M2CSW?-*4(J[XL1_8LZ%1X58C#8BG;DC4Y9QJJ]G=QMR.VO;M<]7K]'/("@`H
M`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"
M@`H`*`"@`H`*`"@#P_\`:;TG5=>_9M_:#T+0M,U#6M;UKX'_`!8TG1M&TFRN
M=1U75M5U'P'K]GI^F:9I]G')/?ZA=7<T,$-O!&\DLDJ(BLS`$`\0_P""</A/
MQ5X%_8Q^#7A;QKX:\0>#O$VE_P#"P_[2\.>*=&U'P]KNG?;OBKXYU&S^W:1J
MUM;W=G]HT^[M+J+S8D\R&ZBE3*2*S`;>5C\S_P#@J'^R'\6_^$MN/''P*\*^
M,_&G@;XP^(]%\2_$GX>^!?#&L>*+C3OBIX2T;Q#I6F>.7TW1+&[N+2SU'P_X
MBUB&::..&+[;).]R\TE[:BW`V\C],/\`@H]X3\5>./V,?C)X6\%>&O$'B_Q-
MJG_"O/[,\.>%M&U'Q!KNH_8OBKX&U&]^PZ1I-M/=W?D:?:7=U+Y43^7#;2RO
MA(V8`'Q!\)_VX_VI_A?\+/AI\-/^';?Q_P!<_P"%=_#_`,&^!?[;\KXBZ9_;
M'_")>'=-T#^U/[-_X47=_P!G_:_[/\_[-]JN?*\[R_.DV[V`/I_X"?MK?'WX
MM?%CPI\/?&O["OQ@^#?ACQ!_;O\`:7Q(\4S>-&T+PY_97AK6-;L_MRZM\(-$
MM/\`B8:AIMII<7FZI:_OM4BV>:^V&4#;RL8'_!2OP+\2GM/V<OCI\&?`GBKQ
M]\1_@5\8K/58-%\&Z?KFK:I/X8U:WAU+6;>\TOP_%-=WFBW>H^%-"T^Z9()M
MD&J3HP$%Q<;@#T7_`()O?"CQ=\,OV<+;5/B1HFLZ!\4/BKXV\8_$_P`?V'B.
MTET[7X]6UO57L+!]4TR5(SI-S<:'I.F7S67DV[0OJ+K+#%/YJ*!L<5_P48\"
M?$V&#X!_M#?!'P?KWC7XH_`7XG1W</A[PSH^J:_JNK>#O%%JD7B*Q.C:187E
MQ=V<MSI&EVD\B0%[:VU2\FC="&-`?@=7_P`$SOA-XH^%'[+ND#Q[H/B+PY\0
MOB!XQ\8_$#QKI_BZ+4;;Q/\`VIJ.IC1+"YUJUU;_`$NSO+GP_H&CW30SK')N
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M6XFT^2[L+Z!+A(S&TEE.@8M"X4`X_P#X:Q_98_Z.6^`'_AY/AU_\T=`'G/Q(
M^+/[#OQ8T?\`L;QM\>?V>-2BB#FQOX_C+\.[75]*E<8,VF:E#XC$UJQ."R9:
M*3:!)&X&*]G)<_S7A[$?6<KQ4L.W;GIOWJ51=JE-^[+R>DH_9DF>%GW#63<2
M87ZKFV#C7C&_LZB]VM1;ZTJJ]Z/G'6$K+GC):'R+%+^SE\*]%\2Q^"/VK?@'
MXFTZ[NH]6MK>X^+7P\B\4^;"B6UKIG^C>(OLM_!%OEF\X"V8LS9CP,U^:?2&
M>?>(F79?G.5TJD<TR+#2HK+Z"YZ=;GJ.;KT$[U/;2G*GSTI*453H*2J-^Z=7
MA=P]@N`I9GET:T:V!S.M&NL157)B*;A!0C1J\O[N5**YY1J+EDYU&O9I:FY\
M-OVDO@QH!3[=\8_A!`\;[F>;XL?#L;B3DL3_`,)-R23DGU-?@/`.3\9912IP
MQW#.8T:E-ZRJ4&N=WOS7;NV[ZM];GZEF6)RZNGR8ZC:VREL>J^,?VM?@7K%@
M8HOC7\&976/:JI\6?AUNX7``'_"3"OT3B27$N881PIY!C:DE&R4:.NVUKGE8
M%8##U+O&4HJ_\W_`/+?A+^T'\%=#\4ZIJ]_\<?@_HXFET9+9I?BWX`2"Z2;7
M+.TU"VN8XO$K*]M_9-S?3M)(NV(VR2!E91N_-/#GASC+*>)<SS7%Y#F.6QKS
MP,:3G2J1A4C/'X>CB*5:*O%T_J=7$5I3DN6DZ4:G/%I<WIYQC,OKX6E1IXFC
M4Y54;2DKQM2E*$HMV:?M(QBDM9<S5M6?;'_#4_[*W_1RW[/_`/X>3X=?_-'7
M]7?5UV/A><4?M4?LJ@C_`(R5_9_P.W_"Y/AT/_=CXIQP\;ZK3L'/V7Z%C_AK
M#]EC_HY;]G__`,/)\.O_`)HZZ"#Y%G^/7[-MKXA\<S:IXI_9W\<_VUXIU34=
M(UFZ^/WPAL?*T^ZV+!"!-XH::*+>KRY'EL/-/&17\R5.%,UPN=\8U,=X3PXM
M6;9OC,5@\;4S#!891P]:RIPM.;JPC=.KS+DFN=Z)JY]C''47AL!&EGKR_P"K
MT*<*E*-*I+WUN]$HM].JT.F\-?&SX#:5??".'6?VC_V?[RW\/V?CN#6Y(OCC
M\-[B'1K77K-HM+TE)IO%`FNXXHG^SJ\:N%V8!V*I/O9#P+Q-EV-\,:>9T?K>
M'R.AQ%3Q\HUXU(8&CF-!PPF#4YS]K6C"$O8J5-3C"W*G[.,9/FQ698.I3SET
M)>SEB)81TDXN+J2I2O4J-)<L7)^\T[7OW;+?A_\`:Q^%'PSTU_!>G_%_]GWQ
MIIEC/=KX6UZT^/\`\*]-C2RNKB6X@M]<MKOQ&)(7@>9@SQ\,HVJ3@-77DB\0
M>`,!/A3`\)+BK+\).LLIS&ECL/A8JA6JSJPIXZE5M.$J,JC<I1<5*/N0;LJC
MC$?V5F=58ZICOJ%6:C[>C*E*;YDDFZ3CHU)+1/9ZOL:$7QO_`&=],^$OC31)
M?VEOV>M4\8>+EUW6M2BL_C/\-XK9];UD*39VDD_B5%$4:1Q1AW*ABK'@$5VT
MN",YR_PTXKRFIR9AQ1Q,LPQ^*A0:A2EC\<HWHT95)1CR0C"$.:3C%R4FK1:,
MWF.'GG&!K1O1P6"]E2@Y+WE2I_:DE=W;;=E>R\R3XB_M#?L[ZO\`"GP]H&G_
M`!\^`.JZI8/X/>]T?_A=GPP@\V/2TM_[0MFGG\4K%MQ&\9(<YW9&:OC?AO.<
MR\-LCR7!Y2\RS'!?V,Z^"]K1I\RPL*:Q%-U*DXTK>ZX-J3O>\>8G+,7A\/F^
M(Q%2O["C/ZQR5.63LZC?([)-]4]O4QO#?[17[*ES=WVD'Q'^SSX"M-?T;5M%
MO_$EI\??@]<RVEI>VDFZ/[-9^(A+*))DA4!3@-M9N`:\O(\B>*Q&,RNKX11X
M.PF<8'&X'$9I2S#`UIT*.(H23C[*BE4E[2<812CHI<LI>ZF;XG$^RA3K1SYX
M^>&JTZL*$J56*E*,EK>6BLF]^EUNRSHO[87PY\(Z':^"H?BS^SKK][I-NNEZ
M+XKC_:!^%UIH4]C`/)LKO4K.7Q(+J&2*W5`\*X9]G!!.3OE.-\3^&,HP_"=+
M@VCG&*RVG'"8'-XX^C2P$\/3]RA6Q-"=L1&5*DHJ=-2A.KRZ--W<UZ62XNO/
M'/,)86G5?M*F'=*3JJ<M91A)>XU)WM+97+%I\9/V5O$'Q"\3ZUX_^-W[-&JV
MESH'A6*RNG^,7PWN+#^U;:R:+6%T^&7Q1]HBA$H4`S(I957D\UT83@)YQQOQ
M#FW&60X/'X;$Y=E$*%7X\/\`7*6'Y,:L-"4_;PIJI9)UH1;BHV;U(GFGU7+<
M)0R[%5*$X5J[E%>[/V;E>GSM+E;M_*][G'77QB_9XL=,\7Z5H?QS_9]M+"X^
M*GAK6]#LK;XU_"V*#_A'].>W,]S"A\6`0QQ['/EMM<_PJ:^7K^'V=83`<3Y?
ME.1_5L)B.+<MQ^!HTZE",'E^'<>>K!.K[D86?N3Y:C^S!G=#-<-*K@JM?$\U
M2&`K4JLFI-^VG>T7[NK=]U==V=%X[^+O[-Y\:^'O$_A#]I3X`_V;>^+=!U?Q
MAHB?&GX:0P?;-,N=T?B2".7Q,J^>+:2XCG6/YW+JX#EGQ['&?AQF;XLR/B'A
MA2^H8K.<NQN=8",Z<*7M\)6YHYG3C-Q7/[*=6.(C3?/.4E-1FYS<>;+\VHK`
MXG"8S2K3P]:GAJEFWRU(ZT6UTYDG!O1:K2R+UI^U-\%?ACJ_B2VT'XT?`'QM
MX5\0ZU>>(=-%A\>?A=IFI:-J&IE'O;*\COO$>V:S,J@I+'G:.3R2H[L+A>,O
M#[,\^P^3<-/BSAS.\=7S+#>PQE'"XG`XG%<KK8>M&NFIT7)+V<XWY8KFE)N3
MA'.<\OS2CA98C&?V?B\-2C1GS4Y3A4A"_+*+AM*SU3WZ=SF=;^-_P1O?"?B_
M7;[]H/\`9XN_&WC#Q-X8U>7P_IWQP^&7D:;I7AZ[A^Q::M_<>)TBFN$MED,D
MH.TDKMW$'/SV;\#\7XOAKBC.<5E]/%<6\4YIE6,GEN&K4U3PN$RVK!4,,L15
MG&E.I"ES.K.,N5^[R\TD[]6'S+`4L9@L/3JNG@,#0KTU6G%ISJ5HOFGR13:3
MDURIJ^]['4Z[^U?\#OB9HNI^$-8^*WP,\%PWEK]KLO$%S^T)\)=3@M-5TZ:&
M]TU);2Q\0^:T4MQ$J,RYVJS'!.!7T6<1XM\0,IS#AC->":_"E+%4O;4,QJYE
MA,53HXO#5(5\-&='#Q]HX5*D%"<HWY8MNS=D<F'^HY37I8RAF,<:Z<N65&-&
MI3<J<TXS:E+W4TG=+JRGJ?[8/P[\3Z!/X)G^+?[.VB:AJ5HVDZQXOF_:`^%E
MQH<=E.GV>^O]/LH/$9N9)YH&<I"1E#)STXY\PQOBCQ!DM;A*MP?2RG&XZB\%
MC<ZGCZ%3`QP\X^SKXC#T*?[^4ZU-RY*2;E3<M=M+I4LEP>(CCHX^5:E2E[2G
MAE2E&KS+6,)R?N)1=KRZH?J'Q[_9Y\!ZQ;ZQX0^//[/GC'0KSPAIO@_Q)X=?
MXX_#/3M2E@TF`6MIJ5E-<>)1#*SV[,DL)(/S,5^\#'6,X1SK@W-*&9\,9/'B
MC)L5DN%R3,\LE7IX;$RA@Z:HTL51G4?LY\]*\:M*]]9<J?.I4U3QV&QU"5#&
M5W@:]/$3Q-"LHN4$ZCYI0DHZJTM8R]+[6<OPG^//[,^B>)_$7B<_&7]G/P#H
MVIZ3I^EZ=X<C^.GPVU"]\RUN))I[^Z:W\2-%!YN5'E[RW`X[MMX;\)X[*N(<
M\XAGPQ2X.RS'X2AA,-EJQ4<57YJ51SJ8BJX<T*?M++W.?FVO'1RDLWQU.KA,
M-A%C98^M1J3G.MR.$;25E"*=F[=[6_2+P[^T_P#LY?##2?B;KEE\7O@/J5Y?
M^.[J[T;2-(^,?PW-WJ.A7$]K%:20"PURZDBMH!/>3"%H<J/,RJALUSY'@<W\
M/,L\0<XPO"%7,<5B^(:U;`8'!6=;%9=4J4H4)4UAJ>)G"E1]I7JQI.DG!<]X
MP3N/$U*&:5LJP\\>J$*>%C&I4J:1A52DY)\S@G*5HIROKIJSL/B3^TI^SCKX
M^'LFE_M#_`*<Z3X^\/:WJ:#XT_#2(V>G6L=U]JG;SO$Z>9Y;2H"J`N<\*:^H
MX^R;-<[7`\\MP4JSRSB/+,?BX\\(.AA:4:WMJCYY0YO9N<4XPO-WTB]3CRNO
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M1@[0GRN/,N_*]4;/_#6/[+'_`$<M\`/_``\GPZ_^:.O5,`_X:Q_98_Z.6^`'
M_AY/AU_\T=`!_P`-8_LL?]'+?`#_`,/)\.O_`)HZ`#_AK']EC_HY;X`?^'D^
M'7_S1T`'_#6/[+'_`$<M\`/_``\GPZ_^:.@`_P"&L?V6/^CEO@!_X>3X=?\`
MS1T`'_#6/[+'_1RWP`_\/)\.O_FCH`/^&L?V6/\`HY;X`?\`AY/AU_\`-'0`
M?\-8_LL?]'+?`#_P\GPZ_P#FCH`/^&L?V6/^CEO@!_X>3X=?_-'0`?\`#6/[
M+'_1RWP`_P##R?#K_P":.@`_X:Q_98_Z.6^`'_AY/AU_\T=`!_PUC^RQ_P!'
M+?`#_P`/)\.O_FCH`/\`AK']EC_HY;X`?^'D^'7_`,T=`!_PUC^RQ_T<M\`/
M_#R?#K_YHZ`#_AK']EC_`*.6^`'_`(>3X=?_`#1T`'_#6/[+'_1RWP`_\/)\
M.O\`YHZ`#_AK']EC_HY;X`?^'D^'7_S1T`'_``UC^RQ_T<M\`/\`P\GPZ_\`
MFCH`/^&L?V6/^CEO@!_X>3X=?_-'0`?\-8_LL?\`1RWP`_\`#R?#K_YHZ`#_
M`(:Q_98_Z.6^`'_AY/AU_P#-'0`?\-8_LL?]'+?`#_P\GPZ_^:.@`_X:Q_98
M_P"CEO@!_P"'D^'7_P`T=`!_PUC^RQ_T<M\`/_#R?#K_`.:.@`_X:Q_98_Z.
M6^`'_AY/AU_\T=`!_P`-8_LL?]'+?`#_`,/)\.O_`)HZ`#_AK']EC_HY;X`?
M^'D^'7_S1T`'_#6/[+'_`$<M\`/_``\GPZ_^:.@`_P"&L?V6/^CEO@!_X>3X
M=?\`S1T`'_#6/[+'_1RWP`_\/)\.O_FCH`/^&L?V6/\`HY;X`?\`AY/AU_\`
M-'0`?\-8_LL?]'+?`#_P\GPZ_P#FCH`/^&L?V6/^CEO@!_X>3X=?_-'0`?\`
M#6/[+'_1RWP`_P##R?#K_P":.@`_X:Q_98_Z.6^`'_AY/AU_\T=`!_PUC^RQ
M_P!'+?`#_P`/)\.O_FCH`/\`AK']EC_HY;X`?^'D^'7_`,T=`!_PUC^RQ_T<
MM\`/_#R?#K_YHZ`#_AK']EC_`*.6^`'_`(>3X=?_`#1T`'_#6/[+'_1RWP`_
M\/)\.O\`YHZ`#_AK']EC_HY;X`?^'D^'7_S1T`'_``UC^RQ_T<M\`/\`P\GP
MZ_\`FCH`/^&L?V6/^CEO@!_X>3X=?_-'0`?\-8_LL?\`1RWP`_\`#R?#K_YH
MZ`#_`(:Q_98_Z.6^`'_AY/AU_P#-'0!H:3^TW^S;KVJZ9H6A?M!_`_6M;UK4
M++2=&T;2?BQX#U'5=6U74;F.ST_3-,T^SU^2XO\`4+J[FA@AMX(WDEDE1$5F
M8`@'(?&O]C/]FS]HGQ5I_C7XQ?#?_A,/$VE^'[7PM8ZG_P`)AX]\/^1H5EJ.
MJZM:V/V+PMXITVTEV:AK>J2^=)`\S?:=C2%(XUC`/'_^'7'["?\`T0S_`,R;
M\8O_`)X-`!_PZX_83_Z(9_YDWXQ?_/!H`/\`AUQ^PG_T0S_S)OQB_P#G@T`'
M_#KC]A/_`*(9_P"9-^,7_P`\&@".+_@EU^PJ8U)^!O./^BF?&$=SV'Q!XJ*;
M;A%O>W];#DK-I:)$G_#KC]A/_HAG_F3?C%_\\&K$'_#KC]A/_HAG_F3?C%_\
M\&@`_P"'7'["?_1#/_,F_&+_`.>#0`?\.N/V$_\`HAG_`)DWXQ?_`#P:`#_A
MUQ^PG_T0S_S)OQB_^>#0`?\`#KC]A/\`Z(9_YDWXQ?\`SP:`#_AUQ^PG_P!$
M,_\`,F_&+_YX-`!_PZX_83_Z(9_YDWXQ?_/!H`/^'7'["?\`T0S_`,R;\8O_
M`)X-`!_PZX_83_Z(9_YDWXQ?_/!H`/\`AUQ^PG_T0S_S)OQB_P#G@T`'_#KC
M]A/_`*(9_P"9-^,7_P`\&@`_X=<?L)_]$,_\R;\8O_G@T`'_``ZX_83_`.B&
M?^9-^,7_`,\&@`_X=<?L)_\`1#/_`#)OQB_^>#0`?\.N/V$_^B&?^9-^,7_S
MP:`#_AUQ^PG_`-$,_P#,F_&+_P">#0`?\.N/V$_^B&?^9-^,7_SP:`#_`(=<
M?L)_]$,_\R;\8O\`YX-`!_PZX_83_P"B&?\`F3?C%_\`/!H`/^'7'["?_1#/
M_,F_&+_YX-`!_P`.N/V$_P#HAG_F3?C%_P#/!H`/^'7'["?_`$0S_P`R;\8O
M_G@T`'_#KC]A/_HAG_F3?C%_\\&@`_X=<?L)_P#1#/\`S)OQB_\`G@T`'_#K
MC]A/_HAG_F3?C%_\\&@`_P"'7'["?_1#/_,F_&+_`.>#0`?\.N/V$_\`HAG_
M`)DWXQ?_`#P:`#_AUQ^PG_T0S_S)OQB_^>#0`?\`#KC]A/\`Z(9_YDWXQ?\`
MSP:`#_AUQ^PG_P!$,_\`,F_&+_YX-`!_PZX_83_Z(9_YDWXQ?_/!H`/^'7'[
M"?\`T0S_`,R;\8O_`)X-`!_PZX_83_Z(9_YDWXQ?_/!H`/\`AUQ^PG_T0S_S
M)OQB_P#G@T`'_#KC]A/_`*(9_P"9-^,7_P`\&@`_X=<?L)_]$,_\R;\8O_G@
MT`'_``ZX_83_`.B&?^9-^,7_`,\&@`_X=<?L)_\`1#/_`#)OQB_^>#0`?\.N
M/V$_^B&?^9-^,7_SP:`#_AUQ^PG_`-$,_P#,F_&+_P">#0`?\.N/V$_^B&?^
M9-^,7_SP:`#_`(=<?L)_]$,_\R;\8O\`YX-`!_PZX_83_P"B&?\`F3?C%_\`
M/!H`/^'7'["?_1#/_,F_&+_YX-`!_P`.N/V$_P#HAG_F3?C%_P#/!H`/^'7'
M["?_`$0S_P`R;\8O_G@T`'_#KC]A/_HAG_F3?C%_\\&@`_X=<?L)_P#1#/\`
MS)OQB_\`G@T`'_#KC]A/_HAG_F3?C%_\\&@`_P"'7'["?_1#/_,F_&+_`.>#
M0`?\.N/V$_\`HAG_`)DWXQ?_`#P:`#_AUQ^PG_T0S_S)OQB_^>#0`?\`#KC]
MA/\`Z(9_YDWXQ?\`SP:`#_AUQ^PG_P!$,_\`,F_&+_YX-`!_PZX_83_Z(9_Y
MDWXQ?_/!H`/^'7'["?\`T0S_`,R;\8O_`)X-`!_PZX_83_Z(9_YDWXQ?_/!H
M`/\`AUQ^PG_T0S_S)OQB_P#G@T`'_#KC]A/_`*(9_P"9-^,7_P`\&@`_X=<?
ML)_]$,_\R;\8O_G@T`'_``ZX_83_`.B&?^9-^,7_`,\&@`_X=<?L)_\`1#/_
M`#)OQB_^>#0`?\.N/V$_^B&?^9-^,7_SP:`#_AUQ^PG_`-$,_P#,F_&+_P">
M#0`?\.N/V$_^B&?^9-^,7_SP:`#_`(=<?L)_]$,_\R;\8O\`YX-`!_PZX_83
M_P"B&?\`F3?C%_\`/!H`/^'7'["?_1#/_,F_&+_YX-`!_P`.N/V$_P#HAG_F
M3?C%_P#/!H`/^'7'["?_`$0S_P`R;\8O_G@T`'_#KC]A/_HAG_F3?C%_\\&@
M#H/"?_!.']C'P-XJ\->-?"WP;_LOQ-X/\0:-XI\.:G_PL/XJWO\`9VN^']1M
@M6TB^^Q:CXYGM+O[/J%I;R^3=030R>7LEC=&92`?_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
